bpc-157 legal status 2026 Exciting news for peptides coming out of today's committee hearing! The FDA Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC- 157 to the 503A Bulks List for use in compounding for Regulatory Alert: The Legal Status

While the FDA notes that compounded medications do not undergo pre-market approval for safety and efficacy, proponents argue that heavily regulated 503A and 503B compounding pharmacies ensure product potency and sterility

Safety standards include: Verified sterile preparation areas CE-marked syringes and pharmaceutical-grade vials Clinical record keeping and follow-up scheduling Adherence to Save Face and GHP accreditations No IV drips or unregulated compounds are used only licensed B12 formulations appropriate for intramuscular use

Science Advances , 7 (2)

Novinscak et al

To examine the nitric oxide-dependency in this system, the rings were pretreated with 0.03 mM L-NAME, an eNOS inhibitor or 10 M hemoglobin, a nitric oxide scavenger